Free Trial
Your Portfolio Deserves Better! MarketBeat All Access for Just $149
Upgrade Now
Claim MarketBeat All Access Sale Promotion

Karyopharm Therapeutics (KPTI) Competitors

Karyopharm Therapeutics logo
$7.14 -0.53 (-6.91%)
Closing price 05/18/2026 04:00 PM Eastern
Extended Trading
$7.15 +0.01 (+0.14%)
As of 05:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

KPTI vs. ANRO, RLMD, AVTE, GYRE, and SLDB

Should you buy Karyopharm Therapeutics stock or one of its competitors? MarketBeat compares Karyopharm Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Karyopharm Therapeutics include Alto Neuroscience (ANRO), Relmada Therapeutics (RLMD), Aerovate Therapeutics (AVTE), Gyre Therapeutics (GYRE), and Solid Biosciences (SLDB). These companies are all part of the "pharmaceutical products" industry.

How does Karyopharm Therapeutics compare to Alto Neuroscience?

Karyopharm Therapeutics (NASDAQ:KPTI) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Karyopharm Therapeutics currently has a consensus target price of $17.17, indicating a potential upside of 140.43%. Alto Neuroscience has a consensus target price of $35.25, indicating a potential upside of 61.41%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Karyopharm Therapeutics is more favorable than Alto Neuroscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Karyopharm Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Alto Neuroscience
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67

Alto Neuroscience has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Alto Neuroscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Karyopharm Therapeutics-129.02% N/A -120.29%
Alto Neuroscience N/A -47.22%-38.81%

66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 1.7% of Karyopharm Therapeutics shares are owned by insiders. Comparatively, 11.3% of Alto Neuroscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Karyopharm Therapeutics has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market.

Alto Neuroscience has lower revenue, but higher earnings than Karyopharm Therapeutics. Alto Neuroscience is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Karyopharm Therapeutics$146.07M1.11-$196.04M-$15.09N/A
Alto NeuroscienceN/AN/A-$63.24M-$2.42N/A

In the previous week, Karyopharm Therapeutics had 2 more articles in the media than Alto Neuroscience. MarketBeat recorded 7 mentions for Karyopharm Therapeutics and 5 mentions for Alto Neuroscience. Karyopharm Therapeutics' average media sentiment score of 0.55 beat Alto Neuroscience's score of -0.07 indicating that Karyopharm Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Karyopharm Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Alto Neuroscience
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Karyopharm Therapeutics beats Alto Neuroscience on 9 of the 16 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Relmada Therapeutics has higher earnings, but lower revenue than Karyopharm Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relmada TherapeuticsN/AN/A-$57.38M-$1.09N/A
Karyopharm Therapeutics$146.07M1.11-$196.04M-$15.09N/A

In the previous week, Relmada Therapeutics and Relmada Therapeutics both had 7 articles in the media. Karyopharm Therapeutics' average media sentiment score of 0.55 beat Relmada Therapeutics' score of 0.10 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Relmada Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Karyopharm Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Relmada Therapeutics has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market.

Relmada Therapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 89.27%. Karyopharm Therapeutics has a consensus price target of $17.17, suggesting a potential upside of 140.43%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Relmada Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Relmada Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71
Karyopharm Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

Relmada Therapeutics has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Relmada Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Relmada TherapeuticsN/A -71.22% -64.46%
Karyopharm Therapeutics -129.02%N/A -120.29%

Summary

Karyopharm Therapeutics beats Relmada Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Aerovate Therapeutics?

Karyopharm Therapeutics (NASDAQ:KPTI) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Aerovate Therapeutics has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Karyopharm Therapeutics-129.02% N/A -120.29%
Aerovate Therapeutics N/A -90.19%-77.47%

Karyopharm Therapeutics presently has a consensus target price of $17.17, suggesting a potential upside of 140.43%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Karyopharm Therapeutics is more favorable than Aerovate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Karyopharm Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Aerovate Therapeutics has lower revenue, but higher earnings than Karyopharm Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Karyopharm Therapeutics$146.07M1.11-$196.04M-$15.09N/A
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A

In the previous week, Karyopharm Therapeutics had 7 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 7 mentions for Karyopharm Therapeutics and 0 mentions for Aerovate Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.55 beat Aerovate Therapeutics' score of 0.00 indicating that Karyopharm Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Karyopharm Therapeutics Positive
Aerovate Therapeutics Neutral

Karyopharm Therapeutics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

66.4% of Karyopharm Therapeutics shares are held by institutional investors. 1.7% of Karyopharm Therapeutics shares are held by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Karyopharm Therapeutics beats Aerovate Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Gyre Therapeutics?

Gyre Therapeutics (NASDAQ:GYRE) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

Gyre Therapeutics presently has a consensus price target of $17.00, suggesting a potential upside of 163.98%. Karyopharm Therapeutics has a consensus price target of $17.17, suggesting a potential upside of 140.43%. Given Gyre Therapeutics' higher probable upside, research analysts clearly believe Gyre Therapeutics is more favorable than Karyopharm Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gyre Therapeutics
2 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00
Karyopharm Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

In the previous week, Karyopharm Therapeutics had 1 more articles in the media than Gyre Therapeutics. MarketBeat recorded 7 mentions for Karyopharm Therapeutics and 6 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 1.08 beat Karyopharm Therapeutics' score of 0.55 indicating that Gyre Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gyre Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Karyopharm Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Gyre Therapeutics has a beta of 2.03, indicating that its stock price is 103% more volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

Gyre Therapeutics has higher earnings, but lower revenue than Karyopharm Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gyre Therapeutics$116.59M5.36$5.03M-$0.09N/A
Karyopharm Therapeutics$146.07M1.11-$196.04M-$15.09N/A

Gyre Therapeutics has a net margin of -5.44% compared to Karyopharm Therapeutics' net margin of -129.02%. Gyre Therapeutics' return on equity of 3.13% beat Karyopharm Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gyre Therapeutics-5.44% 3.13% 2.67%
Karyopharm Therapeutics -129.02%N/A -120.29%

24.0% of Gyre Therapeutics shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 10.0% of Gyre Therapeutics shares are owned by company insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Gyre Therapeutics beats Karyopharm Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Solid Biosciences has a beta of 2.47, meaning that its stock price is 147% more volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market.

Solid Biosciences has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Solid Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Solid BiosciencesN/A -73.42% -61.13%
Karyopharm Therapeutics -129.02%N/A -120.29%

Solid Biosciences has higher earnings, but lower revenue than Karyopharm Therapeutics. Solid Biosciences is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Solid BiosciencesN/AN/A-$174.32M-$1.95N/A
Karyopharm Therapeutics$146.07M1.11-$196.04M-$15.09N/A

Solid Biosciences currently has a consensus price target of $16.36, indicating a potential upside of 151.36%. Karyopharm Therapeutics has a consensus price target of $17.17, indicating a potential upside of 140.43%. Given Solid Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Solid Biosciences is more favorable than Karyopharm Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Solid Biosciences
1 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.92
Karyopharm Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

In the previous week, Solid Biosciences and Solid Biosciences both had 7 articles in the media. Karyopharm Therapeutics' average media sentiment score of 0.55 beat Solid Biosciences' score of -0.14 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Solid Biosciences
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Karyopharm Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 13.6% of Solid Biosciences shares are owned by company insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Solid Biosciences beats Karyopharm Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Karyopharm Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KPTI vs. The Competition

MetricKaryopharm TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$173.82M$3.00B$6.25B$12.29B
Dividend YieldN/A1.98%2.80%5.30%
P/E Ratio-0.4717.2220.6325.23
Price / Sales1.11286.31554.9379.80
Price / CashN/A56.3527.4837.30
Price / Book-0.453.939.696.63
Net Income-$196.04M$74.99M$3.56B$335.59M
7 Day Performance-19.87%-4.47%-1.63%-1.20%
1 Month Performance-17.07%-7.93%-2.59%-1.16%
1 Year Performance39.18%29.34%30.08%28.10%

Karyopharm Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KPTI
Karyopharm Therapeutics
3.2592 of 5 stars
$7.14
-6.9%
$17.17
+140.4%
+34.2%$173.82M$146.07MN/A380
ANRO
Alto Neuroscience
2.5965 of 5 stars
$24.44
+0.7%
$35.13
+43.7%
+756.1%$775MN/AN/AN/A
RLMD
Relmada Therapeutics
2.7948 of 5 stars
$7.36
+0.5%
$12.00
+63.0%
+1,275.3%$767.78MN/AN/A10
AVTE
Aerovate Therapeutics
N/A$25.81
+6.6%
N/A+218.0%$748.10MN/AN/A20
GYRE
Gyre Therapeutics
2.9311 of 5 stars
$7.09
-5.1%
$17.00
+139.8%
-43.3%$724.54M$116.59MN/A40

Related Companies and Tools


This page (NASDAQ:KPTI) was last updated on 5/19/2026 by MarketBeat.com Staff.
From Our Partners